{"id":"amlodipine-low","safety":{"commonSideEffects":[{"rate":"6-10%","effect":"Edema"},{"rate":"3-6%","effect":"Dizziness"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-5%","effect":"Fatigue"},{"rate":"2-5%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amlodipine binds to L-type calcium channels in smooth muscle cells, reducing the influx of calcium ions and subsequent muscle contraction. This leads to vasodilation and a decrease in peripheral resistance, resulting in lowered blood pressure.","oneSentence":"Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:52.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07291375","phase":"EARLY_PHASE1","title":"Role of Amlodipine in Reduction of CIN","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2025-12-20","conditions":"Contrast-induced Nephropathy","enrollment":40},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT07064525","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-12-05","conditions":"Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure","enrollment":252},{"nctId":"NCT06012487","phase":"PHASE1","title":"Correlates and Control of Blood Pressure Variability","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-05-01","conditions":"Blood Pressure Variability","enrollment":10},{"nctId":"NCT06826872","phase":"PHASE2","title":"Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-06-12","conditions":"Hypertension, Essential, Cardiovascular Diseases, Cardiology","enrollment":252},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT04120753","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-26","conditions":"Hypertension, Dyslipidemias","enrollment":106},{"nctId":"NCT06395194","phase":"PHASE3","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"1997-09-27","conditions":"Essential Hypertension","enrollment":15313},{"nctId":"NCT06212648","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-03-25","conditions":"Hypertension, Essential Hypertension","enrollment":253},{"nctId":"NCT05476354","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-05","conditions":"Essential Hypertension","enrollment":271},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT04488978","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-05-21","conditions":"Essential Hypertension","enrollment":440},{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT04191681","phase":"PHASE4","title":"Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-11-08","conditions":"Stage D Heart Failure","enrollment":50},{"nctId":"NCT03783754","phase":"NA","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2018-08-09","conditions":"Stroke, Cerebral Small Vessel Diseases, Intracerebral Hemorrhage","enrollment":4},{"nctId":"NCT03785067","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2020-02-27","conditions":"Cognitive Decline, Intracerebral Hemorrhage, Dementia, Vascular","enrollment":1},{"nctId":"NCT02034435","phase":"PHASE4","title":"Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2013-10","conditions":"Metabolic Syndrome","enrollment":44},{"nctId":"NCT01354613","phase":"NA","title":"Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-04","conditions":"Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension","enrollment":14},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT00891267","phase":"PHASE3","title":"Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-10","conditions":"Metabolic Syndrome, Hypertension","enrollment":60},{"nctId":"NCT03635125","phase":"PHASE4","title":"Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine","status":"COMPLETED","sponsor":"Trinity Hypertension & Metabolic Research Institute","startDate":"2010-08-30","conditions":"JNC 7 Stage 1 or 2 Hypertension","enrollment":40},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT00509470","phase":"PHASE4","title":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT02710552","phase":"PHASE4","title":"Low-dose Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":"Arterial Hypertension","enrollment":100},{"nctId":"NCT02261064","phase":"PHASE1","title":"Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT02194309","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT01631409","phase":"","title":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","status":"WITHDRAWN","sponsor":"City Hospital No 40, Saint Petersburg, Russia","startDate":"2013-09","conditions":"Coronary Heart Disease (CHD)","enrollment":""},{"nctId":"NCT01134393","phase":"PHASE3","title":"TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Hypertension","enrollment":502},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT01956786","phase":"PHASE2, PHASE3","title":"Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine","status":"UNKNOWN","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2013-09","conditions":"Essential Hypertension","enrollment":540},{"nctId":"NCT01848873","phase":"PHASE2, PHASE3","title":"Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine","status":"UNKNOWN","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2013-01","conditions":"Essential Hypertension","enrollment":756},{"nctId":"NCT00454662","phase":"PHASE4","title":"Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)","status":"COMPLETED","sponsor":"COLM Study Research Organization","startDate":"2007-04","conditions":"Hypertension, Cardiovascular Disease, Diabetes","enrollment":5141},{"nctId":"NCT00637078","phase":"PHASE4","title":"STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)","status":"COMPLETED","sponsor":"University of Western Ontario, Canada","startDate":"2008-02","conditions":"Hypertension, Hypercholesterolemia","enrollment":1000},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185},{"nctId":"NCT01197001","phase":"PHASE1","title":"A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT00313547","phase":"PHASE4","title":"High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2006-04","conditions":"Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amlodipine low placebo"],"phase":"phase_2","status":"active","brandName":"Amlodipine low","genericName":"Amlodipine low","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure. Used for Hypertension, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}